Biomedical Engineering Innovation Achievements
First in the World! Sungen Biomedical Obtains FDA's Clinical Trial Approval of IND SGC001 as An Emergency-use Bispecific Antibody Drug for AMI
First in the world! Sungen Biomedical obtains FDA's clinical trial approval of IND SGC001 as an emergency-use antibody drug for AMIOn May 23rd, 2024, Eastern Standard Time, US Food and Drug Administr...
FIC! Sungen Biomedical's SGC001 Injection is Approved for Clinical Trials, Achieving Two Approvals Both in China and the United States!
On August 05, 2024, the world's first innovative drug SGC001 injection obtained the clinical trial implied approval from the Center for Drug Evaluation (CDE). The drug is developed by Beijing Sung...
If you want to know the latest innovations in biology, please visit our website.
Beijing Sungen Biomedical Technology Co., Ltd. with the mission of "Innovate to lead the future and benefit human health", is committed to developing FIC (First in class) antibody drugs, focusing on unmet clinical needs, and striving to become the world's leading antibody research and development (R & D) enterprise.
You must be logged in to post a comment.